1 research outputs found
Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from
Aim of the study: To assess resource utilization
and costs of treatment with lanreotide
AUTOGEL 120 mg (ATG120)
administered as part of routine acromegaly care in Poland.
Material and methods: A multicentre,
non-interventional, observational study
on resource utilization in Polish acromegalic
patients treated with ATG120 at
4 weeks or extended (> 4 weeks) dosing
interval. The study recruited adult acromegalic patients treated medically for
≥ 1 year including at least 3 injections of
ATG120. Data on dosing interval, aspects
of administration, and resource utilization
were collected prospectively during
12 months. Costs were calculated in PLN
from the public health-care payer perspective
for the year 2013.
Results: 139 patients were included in
the analysis. Changes in dosing regimen
were reported in 14 (9.4%) patients. Combined
treatment was used in 11 (8%) patients. Seventy patients (50%) received
ATG120 at an extended dosing interval;
the mean number of days between
injections was 35.56 (SD 8.4). ATG120
was predominantly administered in an
out-patient setting (77%), by health-care
professionals (94%). Mean time needed
for preparation and administration was
4.33 and 1.58 min, respectively, mean
product wastage - 0.13 mg. Patients were
predominantly treated in an out-patient
setting with 7.06 physician visits/patient/
year. The most common control examinations
were magnetic resonance imaging
of brain and brain stem (1.36/
patient/year), ultrasound of the neck
(1.35/patient/year), GH (1.69/pa tient/
year), glycaemia (1.12/patient/year),
IGF-1 (0.84/patient/year), pituitary-thyroid
axis hormone levels assessment
(TSH-0.58/patient/year, T4-0.78/patient/
year). There were 0.43 hospitalizations/
patient/year. For direct medical
costs estimated at PLN 50 692/pa tient/
year the main item was the costs of
ATG120 (PLN 4103.87/patient/month;
97%). The mean medical cost, excluding
pharmacotherapy, was PLN 1445/patient/year (out-patient care - 49%, hospitalization
- 23%, diagnostics/laboratory
tests - 28%).
Conclusions: These results represent
the current use of ATG120 in the population
of Polish acromegalic patients in
a realistic clinical setting. Findings that
50% of patients could be treated with
dose intervals of longer than 28 days
support the potential of ATG120 to
reduce the treatment burden